|
市場調查報告書
神經疾病：早期研究開發與併購決策
Neurological Disease: Early-Stage R&D and Dealmaking
|
神經疾病：早期研究開發與併購決策 是由出版商Decision Resources, Inc.在2009年08月所出版的。
這份英文市場調查報告書包含25 Pages 價格從美金3450起跳。
本研究報告包括神經學新的標的與技術、與初期症狀相關的神經元分解疾病、企業檔案與新藥開發的課題與需求、未來展望等情報，內容摘記如下。
實施概要
序論
神經學市場：變化與技術革新
神經疾病治療的新方法
- 新標的
- Beta-Amyloid
- Beta-Secretase
- Tau蛋白質
- 菸鹼受體
- HMG-CoA還元酵素
- 新技術
企業檔案
- Lundbeck
- CoMentis
- Targacept
- Vitae Pharmaceuticals
未來展望
圖表
Abstract
Introduction
How can early-stage R&D efforts be positioned to tap the remaining opportunity
in the neurology drug market? Although brimming with potential, neurology drug
development is also rife with unique challenges that many companies and agents
have been unable to overcome, as witnessed by the failures of agents initially
deemed highly promising. However, careful planning - including risk mitigation
through strategic collaboration - can allow a drug developer to take advantage
of the significant opportunity in this market.
Questions Answered in This Report
- Although therapies are available for neurological disorders, most of these
conditions remain undertreated, and no cures are available. What benefits do
novel therapies have over existing treatment options? How can companies
mitigate the risk associated with drug development?
- Much of the innovation in drug discovery and design occurs in small
companies. What companies are developing novel approaches to treat
neurological diseases? What collaborations have they forged with Big Pharma?
- The neurology market is entering a period of stagnation. What is currently
driving market growth? What are the greatest needs in the treatment of
neurological diseases?
Scope
- Novel targets for neurology: Beta-amyloid, beta-secretase, tau protein,
NMDA, nicotinic acetylcholinesterase receptor, HMG-CoA reductase.
- Novel technologies for neurology: Deep-brain stimulation, stem cell
therapy.
- Focus on diseases with neuronal degradation as a primary symptom:
Alzheimer' s disease (AD), mild cognitive impairment (MCI), multiple sclerosis
(MS), Parkinson' s disease (PD), Huntington' s disease (HD), ALS and other motor
neuron diseases.
- Company profiles: Lundbeck, CoMentis, Targacept, Vitae Pharmaceuticals.
- Outlook: Challenges in drug development, recent dealmaking, need for
increased research, benefits of academic collaborations.
Mentioned in This Report
Companies
- Abbott
- AC Immune
- Acorda Therapeutics
- Affiris
- Allon Therapeutics
- Apitope International
- Astellas Pharma
- AstraZeneca
- Athersys
- Bayer
- Bial
- Biogen Idec
- Biovail
- Boehringer Ingelheim
- BrainStorm Cell Therapeutics
- Cambridge Laboratories
- CoMentis
- Cytos Biotechnology
- Eisai
- Elan
- Eli Lilly
- Envivo
- Evotec
- Genentech
- Geron
- GlaxoSmithKline
- Intellect Neurosciences
- Johnson & Johnson
- LifeHealth
- Lundbeck
- Medivation
- Merck & Co.
- Merck Serono
- MorphoSys
- Neureva
- NeuroSearch
- Novartis
- Ovation Pharmaceuticals
- Peptimmune
- Pfizer
- Prana Biotechnology
- QR Pharma
- ReceptoPharm
- ReNeuron Group
- Roche
- Stem Cell Therapeutics
- StemCells
- Targacept
- TauRx Therapeutics
- Vitae Pharmaceuticals
- Wyeth
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Neurology Market: Poised for Change and Innovation
- Novel Approaches to Neurological Disease Treatment
- Novel Targets
- Beta-Amyloid
- Beta-Secretase
- Tau Protein
- NMDA
- Nicotinic Receptors
- HMG-CoA Reductase
- Novel Technologies
- Stem Cell Therapy
- Deep-Brain Stimulation
- Company Profiles
- Lundbeck
- CoMentis
- Targacept
- Vitae Pharmaceuticals
- Outlook
Tables
- 1. Descriptions of Select Neurological Diseases
- 2. Top-Selling Products for the Treatment of Neurological Diseases, 2008
- 3. Beta-Amyloid Agents in Clinical Development for the Treatment of
Neurological Diseases
- 4. Beta-Secretase Agents in Clinical Development for the Treatment of
Neurological Diseases
- 5. Tau Protein Agents in Clinical Development for the Treatment of
Neurological Diseases
- 6. NMDA Agents in Clinical Development for the Treatment of Neurological
Diseases
- 7. Nicotinic Receptor Agents in Clinical Development for the Treatment of
Neurological Diseases
- 8. Benefits and Drawbacks of Stem Cell Types in the Treatment of
Neurological Diseases
- 9. Select Companies Developing Stem Cell Therapies
- 10. Select Deals Focusing on the Development of Neurological Disease
Treatments
Figures
- 1. Worldwide Neurology Market Growth, 2004-2008
- 2. Areas of the Brain Targeted by Deep Brain Stimulation
|
